Cancer Genetics Inc (CGIX) Director Purchases $279,000.00 in Stock

Cancer Genetics Inc (NASDAQ:CGIX) Director John Pappajohn purchased 150,000 shares of the stock in a transaction dated Friday, December 8th. The stock was acquired at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the completion of the transaction, the director now directly owns 2,781,204 shares of the company’s stock, valued at $5,173,039.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Cancer Genetics Inc (CGIX) traded down $0.40 on Monday, hitting $1.95. 3,136,900 shares of the company traded hands, compared to its average volume of 252,296. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18. Cancer Genetics Inc has a fifty-two week low of $1.30 and a fifty-two week high of $5.30.

Several research firms have recently commented on CGIX. Zacks Investment Research upgraded shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. HC Wainwright set a $6.00 price target on shares of Cancer Genetics and gave the company a “buy” rating in a research report on Wednesday, November 29th. ValuEngine lowered shares of Cancer Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Maxim Group assumed coverage on shares of Cancer Genetics in a research report on Thursday. They issued a “buy” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.56.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in shares of Cancer Genetics by 44.8% during the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after buying an additional 139,200 shares during the period. Vanguard Group Inc. lifted its stake in shares of Cancer Genetics by 61.9% during the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares during the period. Thompson Davis & CO. Inc. lifted its stake in shares of Cancer Genetics by 5,465.0% during the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after buying an additional 109,300 shares during the period. Granahan Investment Management Inc. MA lifted its stake in shares of Cancer Genetics by 26.3% during the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Cancer Genetics by 61.0% during the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares during the period. 12.71% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Cancer Genetics Inc (CGIX) Director Purchases $279,000.00 in Stock” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/11/cancer-genetics-inc-cgix-director-purchases-279000-00-in-stock.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply